A Phase 1 interventional study of Varenicline Tartrate and Varenicline Tartrate in Smoking Cessation, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2010-01-11.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.
Among the 110 studies testing varenicline in Smoking Cessation, this one is the 84th largest by enrollment, is one of 7 that started in 2007, is one of 6 in phase 1, and was the 15th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 21+
University of Colorado, Denver · Sites in United States, India
Ages 18+
Johns Hopkins University · Sites in South Africa
Ages 18+
University of Maryland, Baltimore · Sites in Botswana
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 25 · Phase 3 30 · Phase 4 47
First in 2000; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 209 across the 110 interventional studies. Of the 97 that completed or were terminated, 61 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 110 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
44 studies in Smoking Cessation by Pfizer: none open now, none under way, none of them phase 3. Of 43 finished, 23 (53%) have results posted.
Among the 44 studies in Smoking Cessation by Pfizer, this one is the 28th largest by enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2007, is one of 8 in phase 1, and was the 16th registered.
Pfizer’s Smoking Cessation studies by the year they started, since 2000.
2 of the studies testing varenicline in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05413122Phase 3Johns Hopkins UniversityEvaluating Smoking Cessation Interventions for PWH in South Africa | 2027-08-31 |
| NCT05694637University of Maryland, BaltimoreBotswana Smoking and Abstinence Reinforcement Trial | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 110 studies testing varenicline in Smoking Cessation, from their registry updates:
Among Pfizer’s 44 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of escalating multiple oral doses of varenicline AMT 8 controlled release formulation for 14 days in adult smokers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
Drug: Varenicline Tartrate
Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
Drug: Varenicline Tartrate
Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
Drug: Varenicline Tartrate
Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
Drug: Varenicline Tartrate
Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
Drug: Varenicline Tartrate
Varenicline 1.8 mg AMT-8 controlled release tablets administered twice a day for 14 days.
Planned dose is Varenicline 2.4 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
Planned dose is Varenicline 3 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
Pharmacokinetic endpoints include varenicline area under the curve from 0-24 hours (AUC24), maximum plasma concentration (Cmax),
Time frame: Day 1 and Day 14
Safety endpoints include evaluation of clinical safety laboratory tests, supine vital signs, triplicate 12-lead ECGs and adverse events.
Time frame: up to 14 days
Time of maximum plasma concentration (Tmax) on Day 1 and Day 14
Time frame: Day 1 and Day 14
Minimum plasma concentration (Cmin), terminal half life (t1/2), observed accumulation ratio (Rac), peak:trough fluctuation (%PTF) on Day 14 only.
Time frame: Day 14
The record gives a start of Oct 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline